Atherosclerosis and arteriosclerosis are both prominent in ESRD, and represent important risk factors for the high incidence of cardiovascular disease deaths in this population.[@bib1], [@bib2], [@bib3] Arteriosclerosis, in particular, is associated with increased aortic stiffness due to enhanced fibrosis, loss of elastic fibers, and extensive vessel wall calcification.[@bib3], [@bib4], [@bib5] In ESRD, elevated aortic stiffness increases SBP and pulse pressure, promoting left ventricular hypertrophy and reduced coronary perfusion.[@bib5], [@bib6] Because the aorta is the principal capacitive element of the arterial tree, measurements of cf-PWV accurately reflect the central effects of increased aortic stiffness.[@bib5], [@bib6], [@bib7] Indeed, increased cf-PWV is strongly associated with adverse outcomes in ESRD,[@bib6], [@bib7] with a rise of 1 m/s increasing adjusted nonfatal cardiovascular events and overall mortality rate by 15%.[@bib7] Dialysis patients with cf-PWV greater than 12.0 m/s are nearly 2 times more likely to die and/or develop nonfatal cardiovascular events compared with patients with values less than 8.8 m/s.[@bib7]

Traditional cardiovascular risk factors, such as age, hypertension, diabetes mellitus, and arteriosclerosis, are overrepresented in chronic kidney disease and are considered to play an important role in the progression of aortic stiffness before development of ESRD.[@bib2], [@bib8] Additional risk factors, however, that are unique to ESRD may account for the increase in aortic stiffness during the course of dialysis therapy.[@bib3], [@bib4], [@bib5], [@bib6], [@bib8] In chronic dialysis patients, chronic exposure to the effects of uremic toxins, fluid excess, abnormalities in bone mineral metabolism, and limited physical activity also may contribute to progression of aortic stiffness.[@bib4], [@bib5], [@bib6], [@bib7], [@bib8] Accordingly, in ESRD, nonpharmacologic strategies aimed at either restoration of renal function (i.e., kidney transplantation), strict control of fluid volume, correction of abnormalities in bone mineral metabolism, and enhanced physical activity have been adopted to decrease progression of aortic stiffness, using cf-PWV to monitor these responses.[@bib6], [@bib7], [@bib8], [@bib9] We conducted a systematic review and meta-analysis of studies in ESRD to evaluate the effect of nonpharmacologic interventions that target aortic stiffness on cf-PWV. Second, we determined effects on SBP and intervention-associated adverse events.

Material and Methods {#sec1}
====================

Data Sources and Search Strategy {#sec1.1}
--------------------------------

The review was conducted in accordance with the Cochrane Collaboration methods, Systematic Reviews standards,[@bib10] and PRISMA guidelines.[@bib11] The study protocol has been previously published[@bib12] and registered in PROSPERO ([www.crd.york.ac.uk/prospero](http://www.crd.york.ac.uk/prospero){#intref0010}) (CRD42016033463). A comprehensive, systematic search strategy ([Supplementary Appendix S1](#appsec1){ref-type="sec"}) was implemented using MEDLINE, EMBASE, Cochrane Central databases, Cochrane Register of Controlled Trials, Cochrane Methodology Register, Health Technology Assessment Database, "Grey Matters Light" of the Canadian Agency for Drugs and Technologies in Health, OVID, EBM Reviews, and grey literature for studies published between January 1965 and March 2018. The original search strategy aimed to capture both pharmacologic and nonpharmacologic interventions that targeted aortic stiffness.

Study Screening, Inclusion, and Exclusion {#sec1.2}
-----------------------------------------

All abstracts and titles were screened by 2 independent reviewers using prespecified criteria. Abstract selection was restricted to those published in English, French, Italian, or Spanish. Nonhuman, *in vitro*, modeling and pediatric studies or systematic/narrative reviews were excluded. Full-text eligible reports underwent screening of the Materials and Methods section to confirm that adult patients with ESRD (\>18 years) were included, that cf-PWV was incorporated, and that an intervention on aortic stiffness was tested. One of the reviewers screened all full-text copies while a second reviewer randomly verified 75% of all reports. Selected reports underwent full-text review by 2 reviewers for final inclusion-decision using prespecified criteria ([Supplementary Appendix S2](#appsec1){ref-type="sec"}). Eligible studies were then abstracted by 2 independent reviewers using a piloted, standardized electronic form. All disagreements were resolved by consensus and consultation with a third independent reviewer. If data from selected studies were incomplete, attempts were made to contact the principal study author.

Randomized controlled trials and nonrandomized studies (cohort, case-control, cross-sectional, and single cohorts with before-and-after design) involving adults (\>18 years) with ESRD of any duration, receiving or not renal replacement therapy (hemodialysis, peritoneal dialysis, transplantation) were included provided that 10 or more participants received the intervention and its effect was assessed by cf-PWV. We distinguished between pharmacologic and nonpharmacologic interventions. The impact of pharmacologic interventions on cf-PWV will be the subject of a separate review and analysis. Kidney transplantation as nonpharmacologic intervention was studied when it was compared with dialysis therapy in before-and-after study designs and/or prospective cohort or cross-sectional studies.

Outcomes {#sec1.3}
--------

The primary outcome was reduction in cf-PWV by the nonpharmacologic intervention, and secondary outcomes included effects on SBP and incidence of intervention-associated adverse events.

Methodological Quality {#sec1.4}
----------------------

The risk of bias was evaluated by 2 independent reviewers using the Cochrane Collaboration tool in randomized studies.[@bib10] For nonrandomized studies, we used "SIGN50" for cohort and case-control studies[@bib13] and the National Institutes of Health Quality assessment tool for cross-sectional studies and single cohorts with before/after design.[@bib14] Specific coding instructions were provided to reviewers and were piloted before implementation.

Statistical Analyses {#sec1.5}
--------------------

Mean differences between end-of-treatment and pretreatment baseline cf-PWV were computed using the reported means and SDs. If different measures of central tendency and distribution were available, means and SD were estimated according to algorithms described by Luo *et al.*[@bib15] and Wan *et al.*[@bib16] Subsequently, weighted mean differences between intervention and comparator were estimated using the final number of participants for each arm of the study. When appropriate, pooled mean differences and 95% CIs were calculated for each intervention using the method of the inverse variance and data were modeled according to the DerSimonian-Laird Method[@bib17] (random effects model) (*P* \< 0.05). To reduce "double-counting" error in crossover studies and single cohorts with before/after design, 50% of the total number of study participants were included in each study arm. Statistical heterogeneity was reported by the *I*^2^ test. Intergroup differences were analyzed using the Cochrane χ^2^ test with *P* ≤ 0.10. Publication bias was investigated if the number of studies per intervention was ≥10. All analyses were performed using RevMan 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). To explore clinical and statistical heterogeneity, effect estimates were reported from different subgroups classified according to mean age and treatment duration. Sensitivity analyses comprised examination of effect model, parameter estimates, study design, and methodological quality.

Quality of Evidence {#sec1.6}
-------------------

Two reviewers evaluated quality of evidence according to 5 domains of GRADE recommendations.[@bib18] Quality was reported as very low, low, moderate, or high for each of the outcome measures according to each intervention.

Results {#sec2}
=======

Search Results {#sec2.1}
--------------

The search strategy identified 6609 citations ([Figure 1](#fig1){ref-type="fig"}). After initial screening, 93 reports remained for full-text screening and abstraction. Of these, 51 studies that evaluated at least 1 intervention on cf-PWV were selected, including 33 reports (17 randomized; 16 nonrandomized) associated with nonpharmacologic interventions, and 18 studies (13 randomized and 5 nonrandomized) with pharmacologic interventions. Publication years ranged from 1989 to 2018, with 45 reports (88%) since 2000. Based on clinical and methodological features, 27 of the 33 reports dealing with nonpharmacologic therapies were appropriate for meta-analysis and classified into 4 different interventions ([Table 1](#tbl1){ref-type="table"}). Three additional reports were reported descriptively. We did not identify any citation that specifically assessed the long-term effects of frequent hemodialysis on cf-PWV as a strategy to decrease the progression of aortic stiffness in ESRD. In addition, 3 studies that assessed the effects of dialysis modality were not included in the primary intervention groups and are reported descriptively. These citations included 1 randomized study[@bib19] reporting that hemodiafiltration (*n* = 103) did not have a significant effect on cf-PWV compared with hemodialysis (*n* = 86); a randomized crossover study[@bib20] showing that 24 weeks of hemodialysis treatment with high-flux polyamide membranes (*n* = 23) decreased cf-PWV compared with low-flux polyamide membranes (*n* = 19); and another randomized trial that found no difference in cf-PWV between low-flux hemodialysis (*n* = 14) and predilution online hemofiltration (*n* = 13).[@bib21]Figure 1PRISMA flowchart. AV, arteriovenous; CKD, chronic kidney disease; PWV, pulse wave velocity.Table 1Studies included in the quantitative analysis classified by contribution to the tested interventionAuthor, referenceStudy designQuality[a](#tbl1fna){ref-type="table-fn"}Intervention (*n*)Comparator (*n*)Age (yr)\
intervention;\
comparatorExposure (mo)Dialysis vintage (mo)\
intervention; comparator1. Kidney transplantationBachelet-Rousseau *et al.*[@bib22]Cohort, before/afterAcceptable[b](#tbl1fnb){ref-type="table-fn"}KT (*n* = 39)Transplant wait-list (on HD or PD)\
(*n* = 49)55 ± 8;\
57 ± 171221 ± 16;\
16 ± 15Ignace *et al.*[@bib23]Cohort, before/afterGood[c](#tbl1fnc){ref-type="table-fn"}KT (*n* = 52)Pretransplant\
HD (48%), PD: 39%, ND: 13%50 ± 13386 ± 74Kaur *et al.*[@bib24]Cohort, before/afterFair[c](#tbl1fnc){ref-type="table-fn"}KT (*n* = 23)Pretransplantation\
HD (86%), PD: 4%,36 ± 9324 ± 19Zoungas *et al.*[@bib25]Cohort, before/afterPoor[c](#tbl1fnc){ref-type="table-fn"}KT (*n* = 31)Pretransplantation46 ± 111226 ± 28Stompor *et al.*[@bib26]Cohort, before/afterUnacceptable[b](#tbl1fnb){ref-type="table-fn"}KT (*n* = 10)Transplant wait-list (on PD)\
(*n* = 9)39 ± 11;\
42 ± 912UnreportedKeven *et al.*[@bib27]Cohort, before/afterUnacceptable[b](#tbl1fnb){ref-type="table-fn"}KT (*n* = 28)HD (*n* = 23)34 ± 9;\
36 ± 111240 ± 35;\
52 ± 20Hornum *et al.*[@bib28]Cohort, before/afterUnacceptable[b](#tbl1fnb){ref-type="table-fn"}KT (*n* = 40)HD and PD (*n* = 40)38 ± 13;\
47 ± 111228 ± 32;\
46 ± 39Covic *et al.*[@bib29]Cross sectionalUnacceptable[b](#tbl1fnb){ref-type="table-fn"}KT (*n* = 20)HD (*n* = 41)40;\
42339 ± 24;\
42 ± 39Pan *et al.*[@bib30]Cross sectionalUnacceptable[b](#tbl1fnb){ref-type="table-fn"}KT (*n* = 20)HD (*n* = 20)57 ± 11;\
43 ± 31238 ± 4;\
39 ± 4Posadzy- Malaczyñska *et al.*[@bib31]Cross sectionalUnacceptable[b](#tbl1fnb){ref-type="table-fn"}KT (*n* = 35)[d](#tbl1fnd){ref-type="table-fn"}HD (*n* = 35)44 ± 2;\
43 ± 3[e](#tbl1fne){ref-type="table-fn"}44 ± 6 after transplant39 ± 3;\
38 ± 4[e](#tbl1fne){ref-type="table-fn"}2. Control of extracellular fluid volumeOnofriescu *et al.*[@bib32]Parallel RCT (1 center)Low risk bias[f](#tbl1fnf){ref-type="table-fn"}Bio-electrical impedance guided UF (*n* = 71)Clinically guided UF (*n* = 64)52 ± 131259 ± 60Hur *et al.*[@bib33]Parallel RCT (2 centers)Unclear risk bias[f](#tbl1fnf){ref-type="table-fn"}Bio-electrical impedance guided UF (*n* = 64)Clinically guided UF (*n* = 62)51 ± 13;\
52 ± 111264 ± 46;\
60 ± 44Onofriescu *et al.*[@bib34]Parallel RCT (1 center)Unclear risk bias[f](#tbl1fnf){ref-type="table-fn"}Bioelectrical impedance guided UF (*n* = 62)Clinically guided UF (*n* = 69)52 ± 13;\
54 ± 1330107 ± 60;\
104 ± 57Lin *et al.*[@bib35]Cross sectionalFair[c](#tbl1fnc){ref-type="table-fn"}Normovolemia ECF/ICF:\
≤95th percentile (*n* = 107)Hypervolemia\
ECF/ICF:\
\> 95th percentile (*n* = 50)56 ± 17;\
57 ± 11N/A37 ± 42;\
64 ± 61Bia *et al.*[@bib36]Cross sectionalPoor[c](#tbl1fnc){ref-type="table-fn"}Normovolemia (OH/ECF: \<15%) (*n* = 40)Hypervolemia (OH/ECF: \>15%) (*n* = 12)56 ± 17;\
65 ± 12N/A72 ± 59;\
68 ± 73Kocyigit *et al.*[@bib37]Cross sectionalPoor[c](#tbl1fnc){ref-type="table-fn"}Normovolemia\
FO 10th to 90th percentile (*n* = 35)Hypervolemia\
FO \> 90th percentile (*n* = 25)45 ±11;\
49 ±16N/A42 ± 33;\
39 ± 34Mitsides *et al.*[@bib38]Cross sectionalPoor[c](#tbl1fnc){ref-type="table-fn"}Normovolemia\
OH/ECW \< 7% (*n* = 30)Hypervolemia\
OH/ECW \>7% (*n* = 42)53 ± 16;\
60 ± 12N/A64 ± 66;\
79 ± 98Siriopol *et al.*[@bib39]Parallel RCTHigh-risk bias[f](#tbl1fnf){ref-type="table-fn"}Lung-US + bio-impedance--guided UF (*n* = 119)Clinically guided UF (*n* = 122)59 ± 15;\
59 ± 132450 ±54;\
48 ± 53Liu *et al.*[@bib40]Parallel RCTLow-risk bias[f](#tbl1fnf){ref-type="table-fn"}Low sodium dialysate (136 mmol/l) (*n* = 28)Standard sodium dialysate (138 mmol/l)\
(*n* = 29)59 ± 10;\
57 ± 111253 ± 65;\
63 ± 743. Low calcium dialysateLeBeouf *et al.*[@bib41]Random Latin square crossoverUnclear risk bias[f](#tbl1fnf){ref-type="table-fn"}Low calcium (1.0 mmol/l)\
(*n* = 18)High calcium (1.50 mmol/l)\
(crossover)49 ± 181 dialysis session × treatment20 ± 24LeBeouf *et al.*[@bib42]Parallel RCTUnclear risk bias[f](#tbl1fnf){ref-type="table-fn"}Low calcium (1.12 mmol/l)\
(*n* = 14)High calcium (1.37 mmol/l)\
(*n* = 13)68 ± 12;\
66 ± 1366 ± 4;\
6 ± 4Masterson *et al.*[@bib43]Parallel RCTUnclear risk bias[f](#tbl1fnf){ref-type="table-fn"}Low calcium (1.3 mmol/l)\
(*n* = 22)High calcium (1.6 or 1.75 mmol/l)\
(*n* = 20)53 ± 21;\
48 ± 111225 ± 29[g](#tbl1fng){ref-type="table-fn"};\
16 ± 18[g](#tbl1fnf){ref-type="table-fn"}Marchais *et al.*[@bib44]Parallel RCTHigh risk bias[f](#tbl1fnf){ref-type="table-fn"}Low calcium (1.50 mmol/l)\
(*n* = 13)High calcium (1.75 mmol/l)\
(*n* = 13)Not reportedSingle dialysisNot reportedMoor *et al.*[@bib45]Randomized crossoverHigh risk bias[f](#tbl1fnf){ref-type="table-fn"}Low calcium (0.8--1.0 mmol/l)\
(*n* = 15)High calcium (1.1--1.4 mmol/l) crossover54 ± 161 dialysis session × treatment32 ± 37[h](#tbl1fnh){ref-type="table-fn"}He *et al.*[@bib46]Parallel RCTHigh risk bias[f](#tbl1fnf){ref-type="table-fn"}Low calcium (1.25 mmol/l)\
(*n* = 64)High calcium (1.50 mmol/l)\
(*n* = 64)57 ± 12;\
56 ± 122443 ± 33;\
43 ± 42Kim *et al.*[@bib47]Cohort, before/afterFair[c](#tbl1fnc){ref-type="table-fn"}Low calcium (1.5 mmol/l)\
(*n* = 20)High calcium (1.75 mmol/l)63 ± 12638 ± 10[i](#tbl1fni){ref-type="table-fn"}4. Intradialytic exerciseMihaescu *et al.*[@bib48]Cohort before/afterAcceptable[b](#tbl1fnb){ref-type="table-fn"}Intradialytic exercise (40 min, Borg 12--14)\
(*n* = 18)No exercise (*n* = 14)56 ± 9;\
55 ± 11354 ± 56;\
55 ± 53Toussaint *et al.*[@bib49]Randomized crossoverHigh-risk bias[f](#tbl1fnf){ref-type="table-fn"}Intradialytic exercise (30 min)\
(*n* = 18)No exercise (crossover)68 ± 6[i](#tbl1fni){ref-type="table-fn"};\
65 ± 13[i](#tbl1fni){ref-type="table-fn"}3-mo treatment, 1-mo wash-out35 ± 31;\
72 ± 56Koh *et al.*[@bib50]Parallel RCTUnclear risk bias[f](#tbl1fnf){ref-type="table-fn"}Intradialytic exercise (Borg 12--13,\
45 min)\
(*n* = 15)No exercise (*n* = 16)52 ± 11;\
51 ± 14632 ± 27;\
26 ± 22Cooke *et al.*[@bib51]Parallel RCTHigh risk bias[f](#tbl1fnf){ref-type="table-fn"}Intradialytic exercise (Borg 12--16, 43 min)\
(*n* = 10)No exercise (*n* = 10)58 ± 17;\
53 ± 154Not reported[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10]

Kidney Transplantation {#sec2.2}
----------------------

Nine of 10 eligible studies[@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30] provided effect estimates for 2 separate meta-analyses to compare kidney transplantation with dialysis ([Table 1](#tbl1){ref-type="table"}; [Figure 2](#fig2){ref-type="fig"}). All studies were observational, and quality varied from good (1), to acceptable or fair (2), to unacceptable or poor (7). The first analysis included 223 kidney recipients from 7 transplant cohorts with measurements before and after transplantation (3 to 12 months).[@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28] All studies reported cf-PWV unadjusted for changes in mean blood pressure, except for 2 reports[@bib23], [@bib25] that provided both adjusted and unadjusted values. Kidney transplantation significantly decreased cf-PWV (−0.70 m/s; 95% CI: −1.3 to −0.11; *P* = 0.02) and reduced SBP (−8.3 mm Hg; 95% CI: −13.2 to −3.3; *P* \< 0.001) over pretransplantation. Statistical heterogeneity was low (*I*^2^ = 0%) for both outcomes. A sensitivity analysis that included 2 adjusted cf-PWV values[@bib23], [@bib25] abolished the effect of transplantation on cf-PWV (−0.35 m/s; 95% CI: −0.94 to 0.23; *I*^2^ = 6%; *P* = 0.23). Forrest plots suggested that there were differences in effect size and directionality between studies. Three studies (90 kidney recipients) showed a benefit of transplantation on cf-PWV (−1.43 m/s; 95% CI: −2.3 to −0.6; *P* \< 0.001),[@bib23], [@bib26], [@bib27] whereas 4 others (138 recipients) did not (−0.08 m/s; 95% CI: −0.9 to 0.7; *P* = 0.84).[@bib22], [@bib24], [@bib25], [@bib28] These subgroup differences modified the overall effect estimates (*P* = 0.03), but variations in study quality (*P* = 0.89) and time of posttransplant assessment did not (*P* = 0.63).Figure 2Effect of kidney transplantation on carotid-femoral pulse wave velocity (cf-PWV) in end-stage renal disease. Analysis 1.1 included 113 kidney transplant recipients with cf-PWV measurements before and after transplantation. To reduce "double-counting" error in these studies, 50% of the total number of study participants was included in each comparative arm (before and after transplantation). Analysis 1.2 evaluated the effects of kidney transplantation over dialysis therapy in 157 transplant recipients and 182 dialysis patients matched by age and dialysis vintage. Analysis was stratified according to study quality. All cf-PWV values were nonadjusted for blood pressure. CI, confidence interval.

The second analysis comprised 6 cohort studies with 157 transplant recipients and 182 chronic dialysis subjects matched by age and dialysis vintage.[@bib22], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30] Kidney transplantation marginally reduced cf-PWV (−0.67 m/s; 95% CI: −1.4 to 0.1; *P* = 0.06), but not SBP (−2.4 mm Hg; 95% CI: −7.9 to 3.1; *P* = 0.39) compared with dialysis. A moderate statistical heterogeneity on cf-PWV (*I*^2^ = 36%) was associated with differences in effect size and directionality between studies. Three studies favored transplantation (−1.16 m/s; 95% CI: −1.9 to −0.4; *P* = 0.003),[@bib26], [@bib27], [@bib29] but 3 others did not (+0.22; 95% CI: −0.8 to 1.2; *P* = 0.66).[@bib22], [@bib28], [@bib30] These differences significantly modified overall effect estimates (*P* = 0.03). An additional report[@bib31] excluded from quantitative analyses had longer posttransplant assessments (44.2 ± 2 months) and showed no benefit of transplantation over dialysis (−0.33 m/s; 95% CI: −1.03 to 0.37; *P* = 0.35).

Control of Extracellular Fluid Volume {#sec2.3}
-------------------------------------

Three randomized trials (1 low risk; 2 unclear risk of bias) in hemodialysis patients evaluated the effect of bio-impedance (*n* = 197) to control extracellular fluid volume, compared with clinical and radiographic assessment (*n* = 195) ([Table 1](#tbl1){ref-type="table"}; [Figure 3](#fig3){ref-type="fig"}).[@bib32], [@bib33], [@bib34] Treatment duration varied from 1 year[@bib32], [@bib33] to 2.5 years.[@bib34] In 2 reports published by a single center,[@bib32], [@bib34] use of duplicate patient-specific data between studies could not be verified despite attempts to contact the investigators. These 2 studies were analyzed separately. All individual estimates favored bio-impedance over clinical assessment to improve cf-PWV. Overall, a significant reduction in cf-PWV (−1.90 m/s; 95% CI: −3.3 to −0.5; *P* = 0.008) and SBP (−4.3 mm Hg; 95% CI: −7.7 to −0.93; *P* = 0.01) occurred with bio-impedance compared with clinical measures. Statistical heterogeneity, however, was high for cf-PWV (*I*^2^ = 69%), and subgroup differences according to study center affected overall effect estimates (*P* = 0.008). Forrest plots indicated that the effect size was larger and wider in the 2 studies by Onofriescu *et al.* (−2.63 m/s; 95% CI: −3.7 to −1.6; *P* = 0.00001)[@bib32], [@bib34] compared with Hur *et al.* (−0.72 m/s; 95% CI: −1.7 to −0.2).[@bib33] This variation was attributed to differences in frequency of "dry" weight assessments (2 weeks vs. 3 months) and normovolemic cutoffs ([Table 1](#tbl1){ref-type="table"}). The effect by treatment duration, however, was nonsignificant (*P* = 0.41).Figure 3Effects of interventions to control extracellular fluid volume on carotid-femoral pulse wave velocity (cf-PWV) in end-stage renal disease. Analysis 2.1: Effect of bio-impedance--guided ultrafiltration compared to clinical and radiographic assessment. Analysis 2.2: Effect of normovolemic (*n* = 212) versus hypervolemic "dry" weight status (*n* = 129) measured by bio-impedance. All cf-PWV values were nonadjusted for blood pressure. CI, confidence interval; RCT, randomized controlled trial; UF, ultrafiltration.

To further explore the impact of extracellular fluid volume on aortic stiffness, we performed a separate analysis of 4 cross-sectional studies that assessed hydration status in dialysis, measured by bio-impedance ([Table 1](#tbl1){ref-type="table"}; [Figure 3](#fig3){ref-type="fig"}**)**.[@bib35], [@bib36], [@bib37], [@bib38] Three studies included subjects on hemodialysis and 1 involved peritoneal dialysis. Study quality ranged from fair (1) to poor (3). Normovolemia (*n* = 212) was associated with significantly lower cf-PWV (−2.10 m/s; 95% CI: −3.1 to −1.1; *P* \< 0.0001) and SBP (−12.3 mm Hg; 95% CI: −19.5 to −5.1; *P* = 0.0008) compared with hypervolemia (*n* = 129). Statistical heterogeneity was moderate (*I*^2^: cf-PWV = 48%; SBP = 31%) and this was associated with differences in individual effect sizes. In 1 study,[@bib38] mean differences in cf-PWV were smaller and nonsignificant (−0.80 m/s; 95% CI: −2.1 to 0.5; *P* = 0.21) compared with the other 3 studies (−2.6 m/s; 95% CI: −3.5 to −1.76; *P* \< 0.00001).[@bib35], [@bib36], [@bib37] Moreover, 1 study[@bib36] demonstrated no effect on SBP (0.0 mm Hg; 95% CI: −16.1 to 16.1), but the other 3^35,37,38^ revealed significant reductions (−13.0 mm Hg; 95% CI: −22.3 to 2.8; *P* = 0.01). These variations were associated in part with discrepancies in normovolemic cutoffs.

A randomized study[@bib39] in hemodialysis patients evaluated the effects of lung ultrasonography followed by bio-impedance (*n* = −119) versus a clinical method of "dry" weight assessment (*n* = 122) on cardiovascular outcomes. At 24 months of follow-up, cf-PWV increased significantly (*P* \< 0.001) in both the intervention (+2.87 m/s; 95% CI: 2.57--3.17) and control groups (+2.1 m/s; 95% CI: 1.9--2.3), with no reduction in all-cause mortality or cardiovascular events. In a separate study relevant to control of extracellular fluid volume,[@bib40] hemodialysis patients with predialysis plasma sodium concentration higher than 138 mmol/l were randomly assigned to low sodium dialysate (136 mmol/l) or standard dialysate (138 mmol/l). After 12 months of study, there was no significant difference in cf-PWV between the 2 groups (−0.3 m/s; 95% CI: −0.8 to 0.2; *P* = 0.27).

Low Calcium Dialysate {#sec2.4}
---------------------

Seven hemodialysis studies[@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47] reported effect estimates on use of low calcium (*n* = 151) versus high calcium (*n* = 110) dialysates (2 crossover studies) to reduce cf-PWV ([Table 1](#tbl1){ref-type="table"}; [Figure 4](#fig4){ref-type="fig"}). Only 5 studies[@bib41], [@bib42], [@bib44], [@bib45], [@bib47] reported SBP data. Six studies (3 unclear risk and 3 high risk of bias) were randomized trials and 1 was nonrandomized (fair quality). Calcium dialysate concentrations for low calcium arms ranged from 0.8 to 1.5 mmol/l (mean 1.18 ± 0.25) and between 1.37 to 1.75 mmol/l (mean 1.57 ± 0.16) for high calcium groups. Four studies assessed chronic effects of the intervention (3 to 12 months) and 3 reports evaluated acute effects (\<3 weeks).[@bib41], [@bib44], [@bib45] Overall, low calcium dialysate was associated with reduction in cf-PWV (−1.70 m/s; 95% CI: −2.4 to −1.0; *P* \< 0.00001) with no effect on SBP (−1.6 mm Hg; 95% CI: −8.9 to 5.8; *P* = 0.67), compared with high calcium dialysate. Heterogeneity was low (*I*^2^ = 0%) and differences in study design and risk of bias did not modify overall effect estimates (cf-PWV: *P* = 0.89; SBP: *P* = 0.36). Treatment duration (≤6 months vs. ≥12 months) was not a confounder on effect estimates (*P* = 0.66) and differences in mean age and dialysis vintage were nonsignificant (*P* \> 0.10). A sensitivity analysis on cf-PWV with and without the 3 acute studies did not change overall effect estimates (*P* = 0.92).Figure 4Effect of low calcium dialysate on carotid-femoral pulse wave velocity (cf-PWV) in end-stage renal disease. Studies were stratified based on the duration of effects (acute vs. chronic) and study quality or design. To reduce "double-counting" error in crossover studies (LeBeouf *et al.*[@bib41]; Moor *et al.*[@bib45]) and single cohort studies with before/after design (Kim *et al.*[@bib47]), 50% of the total number of study participants was included in each study arm. All cf-PWV values were nonadjusted for blood pressure. CI, confidence interval; RCT, randomized controlled trial.

Intradialytic Exercise {#sec2.5}
----------------------

Four studies in hemodialysis subjects (1 crossover, 2 parallel trials, 1 cohort) assessed effects of intradialytic exercise (*n* = 61; 1 crossover study) on cf-PWV and SBP relative to nonexercise (*n* = 40) (2 high risk of bias; 1 unclear risk; and 1 acceptable) ([Table 1](#tbl1){ref-type="table"}; [Figure 5](#fig5){ref-type="fig"}).[@bib48], [@bib49], [@bib50], [@bib51] Intradialytic exercise for 3 to 6 months decreased cf-PWV (−1.13 m/s; 95% CI: −2.2 to −0.03; *P* = 0.04) without affecting SBP (+0.5 mm Hg; 95% CI: −9.5 to 10.4; *P* = 0.93) over no exercise. Overall statistical heterogeneity was low (cf-PWV: *I*^2^ = 18%, SBP: 0%), but moderate among studies identified with high-risk bias (*I*^2^ = 34%). Although study quality and design did not impact overall effect estimates (cf-PWV: *P* = 0.53; SBP: *P* = 0.93), Forrest plots indicated that reports by Mihaescu *et al.*[@bib48] and Toussaint *et al.*[@bib49] showed a large benefit of exercise on cf-PWV (−2.35 m/s; 95% CI: −4.02 to −0.67; *P* = 0.006), whereas those by Koh *et al.*[@bib50] and Cooke *et al.*[@bib51] did not (−0.42 m/s; 95% CI: −1.51 to 0.68; *P* = 0.46). These subgroup differences were significant (*P* = 0.06) and were associated with differences in intensity as measured by Borg scale (12--16), length of training blocks (0.5 to 2 hours), and total duration (3 to 6 months) of exercise.Figure 5Effects of intradialytic exercise on carotid-femoral pulse wave velocity (cf-PWV) in end-stage renal disease. Studies were stratified according to the study quality and design. To reduce "double-counting" error in the crossover study (Toussaint *et* *al.*[@bib49]), 50% of the total number of study participants were included in each study arm. All cf-PWV values were nonadjusted for blood pressure. CI, confidence interval; RCT, randomized controlled trial.

Quality of Evidence {#sec2.6}
-------------------

Quality of evidence for both cf-PWV and SBP ([Supplementary Table S1](#appsec1){ref-type="sec"}) ranged from very low to low except for low calcium dialysate, considered of moderate quality.

Adverse Events {#sec2.7}
--------------

[Supplementary Table S2](#appsec1){ref-type="sec"} summarizes adverse events for the interventions and comparators reported in 21 of the 27 studies (78%). No intervention was associated with fatal or severe adverse events.

Discussion {#sec3}
==========

We pooled data from 2166 subjects with ESRD included in 33 reports to evaluate the effects of 4 different nonpharmacologic interventions on cf-PWV. Although quality of evidence ranged from very low to moderate, kidney transplantation, bio-impedance--guided control of extracellular fluid volume, low calcium dialysate, and intradialytic exercise were associated with significant improvements in cf-PWV in ESRD. All nonpharmacologic interventions, except for low calcium dialysate and intradialytic exercise reduced SBP. However, because of the limited information available, effects of antihypertensive medications and variations in heart rate on SBP changes were not accounted for.

Kidney transplantation is associated with improved outcomes in ESRD.[@bib52] Effective restoration of kidney function leads to improvement of endothelial dysfunction, uremic toxin removal, recovery of abnormal mineral metabolism, and improved blood pressure control.[@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30] Our findings suggest that both cf-PWV and SBP are reduced after kidney transplantation. These results confirm a previous meta-analysis[@bib53] that found a reduction in central arterial stiffness posttransplantation. Our analysis, however, indicates that effects on cf-PWV were smaller (−0.70 m/s) than previously reported (−1.20 m/s).[@bib53] Several factors may account for this difference. First, we excluded the report by Kovacs *et al.*[@bib54] who obtained estimates of aortic pulse wave velocity from radial artery waveforms, with effects greater than 2 SDs from the pooled mean differences. Second, we included the study by Stompor *et al.*[@bib26] who measured cf-PWV in transplant recipients (before and after transplantation) and in dialysis patients waiting for transplantation. Third, it is important to note that average baseline cf-PWV in transplant studies was lower than those involving other interventions ([Supplementary Table S3](#appsec1){ref-type="sec"}). This suggests a less advanced degree of vascular stiffness in pretransplant subjects, which may have diminished the impact of transplantation (i.e., "flooring effect"). Transplant recipients also represent a heterogeneous population with varying pre- and posttransplant management, and this might be expected to affect aortic stiffness.[@bib25], [@bib27] Furthermore, selection of control groups in comparative cohort analyses is a potential source of confounding that may have decreased the effect of transplantation.[@bib30] Finally, the inclusion of cf-PWV values adjusted for blood pressure in our analysis abolished the effects of transplantation, highlighting the importance of blood pressure reduction on aortic stiffness.[@bib23], [@bib25] Other risk factors, such as infection, immunosuppression, new-onset diabetes, nonimmunosuppressive drugs, and dyslipidemia were also not accounted for in our analysis, and may have offset the effects of transplantation on aortic stiffness.[@bib22], [@bib24], [@bib25], [@bib28]

Upper-extremity native arteriovenous fistula creation has been associated with sustained reductions in blood pressure, total peripheral vascular resistance, and cf-PWV within the first 3 months postoperatively.[@bib55], [@bib56] However, longer-term adaptive changes that might be associated with arteriovenous fistula use have not been studied. In addition, the persistence of a functioning arteriovenous fistula in kidney transplant recipients has been associated with increased central aortic pulse pressure, and it has been suggested that surgical ligation may lower cardiovascular risk in this population.[@bib57] In our study, we did not include arteriovenous fistula creation as an intervention, because this procedure is considered one aspect of standard of care in hemodialysis, and it is not routinely performed with the unique intention to improve arterial stiffness.

Fluid overload in ESRD is typically assessed by indirect methods.[@bib32] A more objective assessment involves bio-impedance spectroscopy.[@bib32], [@bib33], [@bib34] Our review suggests that strict control of extracellular fluid by bio-impedance decreases aortic stiffness and SBP compared with clinical methods. Remarkably, bio-impedance reduced cf-PWV by approximately 1.90 m/s relative to the conventional method. By implementing bio-impedance measures in ESRD, such reduction could potentially decrease mortality by as much as 28%.[@bib7] Because the quality of evidence was "low" for these studies, additional trials are needed to demonstrate the impact of this intervention on cardiovascular outcomes in ESRD. In addition, the use of lung ultrasonography followed by bio-impedance as a combined method for adjustment of "dry" weight may be less sensitive than bio-impedance alone to reduce cf-PWV.[@bib39] Thus, it is possible that in the absence of adequate control of overall fluid volume by bio-impedance, there may be no benefit to monitoring of pulmonary congestion by lung ultrasonography.[@bib39] Consequently, the use of lung ultrasonography as a tool to improve aortic stiffness will require further study.

Consensus is lacking on the optimal dialysate calcium concentration, although high calcium dialysate may contribute to vascular calcification and aortic stiffness.[@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47] Based on moderate quality of evidence, our findings strongly support use of low calcium dialysate to reduce aortic stiffness in ESRD. This effect was identified in both acute and chronic trial designs. Due to the small number of published reports and wide range of low calcium concentrations, the optimal calcium concentration to decrease aortic stiffness remains to be determined. Our review revealed that there are short- and long-term effects of low calcium dialysate on aortic stiffness. Acute effects appear to be reversible and related to changes in vascular tone from transient variations in calcium flux.[@bib41], [@bib42], [@bib43], [@bib44], [@bib45] Long-term effects, however, may be due to structural changes in the vascular wall associated with changes in bone turnover and regression of vascular calcification.[@bib41], [@bib42], [@bib46]

Physical function and activity are generally low in ESRD, and exercise may improve quality of life.[@bib58] Our findings indicate that supervised intradialytic exercise decreases aortic stiffness in dialysis subjects without altering SBP. The effects of exercise are reversible and may relate to improvements in endothelial function, vascular tone, and/or inflammation.[@bib49], [@bib51], [@bib58] Because our study identified important differences in intensity, time of exposure, and duration of exercise between studies, standardization should be a priority for future trials.

Additional Sources of Heterogeneity {#sec3.1}
-----------------------------------

Several factors may modify the effects of interventions that target aortic stiffness. Because vascular calcification and aortic stiffness have additive prognostic value on cardiovascular outcomes, the beneficial effects of these interventions may be reduced in patients with ESRD with extensive vascular calcification.[@bib7] In addition, differences in predialysis cardiovascular function, effects of cointerventions such as antihypertensive medications or phosphate binders, and the role of inflammation, genetic polymorphisms, vitamin K deficiency, or advanced glycation end-product formation cannot be disregarded as potential sources of variability in the individual responses.[@bib4], [@bib8], [@bib9], [@bib59], [@bib60]

Strengths and Limitations {#sec3.2}
-------------------------

The strength of our study lies in the rigorous methodology, comprehensive search, and detailed quality assessments, which permitted an extensive review of multiple interventions that target aortic stiffness in ESRD. An additional strength is that our findings were restricted to assessments of aortic stiffness using cf-PWV, which is considered the "gold standard."[@bib5], [@bib6], [@bib7], [@bib8], [@bib9] Although different instruments for measuring cf-PWV were identified among studies included in our search, these devices and their techniques have been validated and standardized,[@bib6], [@bib53], [@bib60] and therefore, variability of measurements was minimized. We recognize that quality of evidence is limited by quality and design of studies. Thus, some pooled estimates are hypothesis-generating due to high statistical and methodological heterogeneity, small number of studies, and lack of control for confounders. A few studies were excluded because of insufficient data and lack of author responses to inquiries, but exclusion of these studies is unlikely to affect our conclusions.

In summary, several nonpharmacologic interventions may individually reduce aortic stiffness and SBP in ESRD, with a mean reduction in cf-PWV ranging from 0.70 to 2.61 m/s and average SBP decrease from 4.3 to 13 mm Hg. If effective, these interventions could potentially reduce the risk of cardiovascular events and all-cause mortality in ESRD by approximately 11% to 39%.[@bib7] Accordingly, future trials should address the impact of these nonpharmacologic interventions on cardiovascular outcomes and mortality risk reduction in ESRD.
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**Appendix S1.** Search strategy.

**Appendix S2.** Study selection criteria.

**Table S1.** Quality of evidence.

**Table S2.** Summary of adverse events.

**Table S3.** Pretreatment baseline cf-PWV values.

[^1]: ECF/ICF, extracellular fluid to intracellular fluid ratio; FO, absolute fluid overload; HD, hemodialysis; KT, kidney transplantation; NA, not applicable; ND, nondialysis; OH, overhydration; OH/ECF ratio, overhydration to extracellular fluid ratio; OH/ECW, overhydration index to extracellular water content; PD, peritoneal dialysis; RCT, randomized controlled trial; UF, ultrafiltration; US, ultrasonography.

[^2]: Although tools for observational studies are specific to the methodological design, they are equivalent to the rating level of grading.[@bib13], [@bib14]

[^3]: The "SIGN50" tool for assessing methodological quality in cohort studies: Interpretation: *high quality (++)*: Majority of criteria met. Little or no risk of bias. Results unlikely to be changed by further research; *Acceptable (+)*: Most criteria met. Some flaws in the study with an associated risk of bias. Conclusions may change in the light of further studies; Unacceptable = *Low quality (0)*: Either most criteria not met, or significant flaws relating to key aspects of study design. Conclusions likely to change in the light of further studies.

[^4]: National Institutes of Health quality assessment tool for cross-sectional studies and single cohort before-after (pre-post) studies with no control group. Interpretation: *good quality:* minimal risk of bias, low risk of measurement errors or other confounding factors that may results from "flaws" in the design or conduct of the study (equivalent to low risk of bias); *fair quality;* presence of some confounding, selection, information and measurement bias derived from some "flaws" in the design or conduct of the study; there is some doubt about the ability of the study to accurately assess an association between the intervention or exposure and outcome; *poor quality*: poor internal validity and high risk for "flaws" in the design or execution of the study. There is high doubt about the results reported in the study or the ability of the study to accurately assess an association between the intervention or exposure and the outcome (equivalent to high risk of bias).

[^5]: Effect size: −0.33; 95% confidence interval: −1.03 to 0.37); *P* = 0.35.

[^6]: Values are SE.

[^7]: The Cochrane collaboration's tool for assessing risk of bias in RCTs: Interpretation: *Low risk of bias*: plausible bias unlikely to seriously alter the results; *unclear risk of bias*: plausible bias that raises some doubt about the results; *high risk of bias*: plausible bias that seriously weakens confidence in the results.

[^8]: Estimated from median and interquartile ranges.

[^9]: Estimated from individual values.

[^10]: Estimated from median and range values.
